Clinical Trials Browser

Active not recruiting × INDUSTRY × Abiraterone Acetate × Clear all

NCT05457257 2026-04-21

Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations

Phase 4 Active not recruiting

43 enrolled 16 charts

Metastatic Castration-resistant Prostate Cancer

NCT02123758 2026-04-13

A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer

Phase 1 Active not recruiting

Prostatic Neoplasms

NCT02257736 2026-04-13

An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)

Phase 3 Active not recruiting

982 enrolled 15 charts

Prostatic Neoplasms

NCT03431350 2026-04-13

QUEST

Phase 2 Active not recruiting

136 enrolled 29 charts

Prostatic Neoplasms, Castration-Resistant

NCT03748641 2026-04-13

MAGNITUDE

Phase 3 Active not recruiting

765 enrolled 16 charts 2 FDA

Prostatic Neoplasms, Castration-Resistant

NCT04497844 2026-04-13

AMPLITUDE

Phase 3 Active not recruiting

696 enrolled 15 charts 2 FDA

Metastatic Castration-sensitive Prostate Cancer

NCT04577833 2026-04-13

A Study of Comparative Formulations of Niraparib and Abiraterone Acetate (AA) in Men With Prostate Cancer

Phase 1 Active not recruiting

Prostatic Neoplasms

NCT04662580 2026-04-13

ARX517

Phase 1 Active not recruiting

Prostatic Neoplasms

NCT04493853 2026-04-01

CAPItello-281

Phase 3 Active not recruiting

Prostatic Neoplasms

NCT06421935 2026-03-24

M9466 Alone or in Combination in Advanced Solid Tumors (DDriver 501)

Phase 1 Active not recruiting

Ovarian Neoplasms

NCT05171816 2026-03-11

Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort)

Phase 3 Active not recruiting

110 enrolled 12 charts

Metastatic Castration-resistant Prostate Cancer

NCT03732820 2026-01-29

Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer

Phase 3 Active not recruiting

895 enrolled 19 charts 2 FDA

Metastatic Castration-resistant Prostate Cancer

NCT04446117 2025-12-18

CONTACT-02

Phase 3 Active not recruiting

575 enrolled 13 charts

Prostatic Neoplasms

NCT05367440 2025-12-08

PETRANHA

Phase 1/2 Active not recruiting

Prostatic Neoplasms

NCT03706365 2025-04-20

CYCLONE 2

Phase 2/3 Active not recruiting

393 enrolled 23 charts

Prostatic Neoplasms

NCT04691804 2024-12-31

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer

Phase 3 Active not recruiting

Metastatic Castration-Resistant Prostate Cancer (mCRPC)